Skip to main content
SpringerLink
Log in

Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes

  • Progress in Hematology
  • Transfusional iron overload and iron chelation therapy
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Many patients with bone marrow failure syndromes need frequent transfusions of red blood cells, and most of them eventually suffer from organ dysfunction induced by excessively accumulated iron. The only way to treat transfusion-induced iron overload is iron chelating therapy. However, most patients have not been treated effectively because daily/continuous administration of deferoxamine is difficult for outpatients. Recently, a novel oral iron chelator, deferasirox, has been developed, and introduction of the drug may help many patients benefit from iron chelation therapy. In this review, we will discuss the current status of iron overload in transfusion-dependent patients, and the development of Japanese guidelines for the treatment of iron overload in Japan, which were established by the National Research Group on Idiopathic Bone Marrow Failure Syndromes in Japan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kushner JP, Porter J, Olivieri N. Secondary iron overload. Hematology/American Society of Hematology Education Program Book: American Society of Hematology; 2001.

  2. McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci. 1983;19:205–66.

    Article  CAS  PubMed  Google Scholar 

  3. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007;78:487–94.

    Article  CAS  PubMed  Google Scholar 

  4. Shashaty G, Frankewich R, Chakraborti T, et al. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park). 2006;20:1799–806, 1811; discussion 1811–3, 1817.

  5. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–603.

    Article  PubMed  Google Scholar 

  6. Gattermann N, Porter J, Lopes L, Seymour J. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2005;19:18–25.

    Google Scholar 

  7. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol. 2007;78:540–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996;94:288–99.

    Article  CAS  PubMed  Google Scholar 

  9. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–80.

    CAS  PubMed  Google Scholar 

  10. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–62.

    Article  CAS  PubMed  Google Scholar 

  11. Porter J, Vichinsky E, Rose C, et al. A phase II study with ICL670 (Exjade), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload. Blood. 2004;104:abstract 3193.

  12. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002;87:1286–306.

    PubMed  Google Scholar 

  13. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120:187–200.

    Article  PubMed  Google Scholar 

  14. Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:58–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant (Research on Intractable Diseases) from the Ministry of Health, Labor and Welfare of Japan. The authors thank Dr. Norbert Gattermann for his valuable advice in establishing the guidelines.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan

    Takahiro Suzuki & Keiya Ozawa

  2. Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Masao Tomonaga & Yasushi Miyazaki

  3. Department of Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

    Shinji Nakao

  4. First Department of Internal Medicine (Department of Hematology), Tokyo Medical University, Tokyo, Japan

    Kazuma Ohyashiki

  5. Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan

    Itaru Matsumura

  6. Department of Medicine, Division of Gastroenterology and Hematology/Oncology, Asahikawa Medical College, Asahikawa, Japan

    Yutaka Kohgo

  7. Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan

    Yoshiro Niitsu

  8. Department of Paediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Seiji Kojima

Authors
  1. Takahiro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masao Tomonaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasushi Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinji Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuma Ohyashiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Itaru Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yutaka Kohgo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshiro Niitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seiji Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keiya Ozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keiya Ozawa.

About this article

Cite this article

Suzuki, T., Tomonaga, M., Miyazaki, Y. et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol 88, 30–35 (2008). https://doi.org/10.1007/s12185-008-0119-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-008-0119-y

Keywords

Search

Navigation